Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 1 year agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via Yahoo Finance· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 2 weeks agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoAbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales...
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
Motley Fool· 1 year agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2022 Earnings Call Feb 09, 2023, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus
Benzinga via Yahoo Finance· 1 year agoAbbVie Inc (NYSE: ABBV) has reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the...
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Motley Fool· 1 year agoLast week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 3 weeks agoAbbVie ABBV will report first-quarter 2024 results on Apr 26, before market open. In the last...
Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks
Motley Fool· 2 years agoWith the market down by more than 21% in 2022, we're officially in a bear market, and many investors...